ANL 28.35 Decreased By ▼ -1.65 (-5.5%)
ASC 15.14 Decreased By ▼ -0.56 (-3.57%)
ASL 23.65 Decreased By ▼ -0.55 (-2.27%)
AVN 95.60 Decreased By ▼ -3.20 (-3.24%)
BOP 9.20 Increased By ▲ 0.10 (1.1%)
BYCO 10.07 Decreased By ▼ -0.38 (-3.64%)
DGKC 132.50 No Change ▼ 0.00 (0%)
EPCL 48.70 Decreased By ▼ -0.21 (-0.43%)
FCCL 24.55 Decreased By ▼ -0.50 (-2%)
FFBL 25.63 Decreased By ▼ -0.33 (-1.27%)
FFL 16.00 Decreased By ▼ -0.65 (-3.9%)
HASCOL 11.06 Decreased By ▼ -0.13 (-1.16%)
HUBC 84.20 Decreased By ▼ -0.79 (-0.93%)
HUMNL 7.27 Decreased By ▼ -0.33 (-4.34%)
JSCL 24.65 Decreased By ▼ -1.75 (-6.63%)
KAPCO 36.10 Decreased By ▼ -1.00 (-2.7%)
KEL 4.05 Decreased By ▼ -0.07 (-1.7%)
LOTCHEM 14.76 Decreased By ▼ -0.58 (-3.78%)
MLCF 46.00 Decreased By ▼ -0.73 (-1.56%)
PAEL 38.75 Decreased By ▼ -0.90 (-2.27%)
PIBTL 12.05 Decreased By ▼ -0.40 (-3.21%)
POWER 10.60 Decreased By ▼ -0.35 (-3.2%)
PPL 90.60 Decreased By ▼ -1.00 (-1.09%)
PRL 26.30 Decreased By ▼ -0.85 (-3.13%)
PTC 9.14 Increased By ▲ 0.04 (0.44%)
SILK 1.40 Decreased By ▼ -0.04 (-2.78%)
SNGP 39.00 Decreased By ▼ -0.80 (-2.01%)
TRG 138.75 Increased By ▲ 1.15 (0.84%)
UNITY 32.15 Decreased By ▼ -0.85 (-2.58%)
WTL 1.56 Decreased By ▼ -0.08 (-4.88%)
BR100 4,874 Decreased By ▼ -45.25 (-0.92%)
BR30 25,236 Decreased By ▼ -341.52 (-1.34%)
KSE100 45,363 Decreased By ▼ -366.17 (-0.8%)
KSE30 18,884 Decreased By ▼ -101.17 (-0.53%)

A unit of Novartis AG said on Tuesday it would make partner Adamis Pharmaceuticals Corp's  emergency allergy shots immediately available in local pharmacies across the United States, amid a shortage of Mylan NV's rival product, EpiPen.

The Sandoz unit of Novartis launched Symjepi for use in hospitals in January and had said it would make the treatment available in pharmacies in a phased manner.

Mylan dominates the market for emergency allergy shots with EpiPen, an auto-injector that delivers a dose of epinephrine in the event of severe allergic reactions to a number of triggers, including bee stings or peanuts.

However, there has been a shortage of EpiPens in North America, Europe and Canada due to manufacturing delays. The U.S. Food and Drug Administration in May last year added the treatment to its list of drugs in shortage.

Adamis, which received U.S. approval for its emergency epinephrine syringes in 2017, distributes Symjepi in the United States exclusively through Sandoz.

In a statement, Sandoz said it was making both the adult and pediatric doses of Symjepi immediately available in local pharmacies across the nation.

Copyright Reuters, 2019